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Abstract Osteoarthritis of the hip is a significant source of
morbidity in the elderly. Treatment guidelines are available
for the management of hip osteoarthritis, but these do not
address the application of intraarticular corticosteroid
injection. The intraarticular injection of corticosteroid is used
in the management of other large joint osteoarthritic diseases
and is well studied in the knee, however, this data cannot be
used to make sound clinical decisions regarding its use for hip
osteoarthritis. There are also concerns regarding the safety of
this modality. Review of the published literature reveals that
there are eight trials examining the efficacy of intraarticular
corticosteroid injection for hip osteoarthritis and of these
only four are randomized controlled trials. In general, the
available literature demonstrates a short-term reduction of
pain with corticosteroid injection and is indicated for patients
refractory to non-pharmacologic or analgesic and NSAID
therapy. The use of radiologic-guidance is recommended
and, with proper sterile technique, the risk of adverse out-
comes is very low. Future randomized controlled trials are
needed to further examine the efficacy and safety of intra-
articular corticosteroid injection for hip osteoarthritis.
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Introduction
Osteoarthritis is the most common form of arthritis in the
United States and osteoarthritis of the hip is a significant
cause of morbidity in the elderly [1–6]. There are standard
treatment guidelines for the management of hip osteoar-
thritis; however, these typically do not include intraarticular
steroid injection as a possible therapeutic modality second-
ary to potential side effects of these injections and the paucity
of studies looking at this intervention [7–14]. Intraarticular
injection of steroid is mostly used for large joint inflamma-
tory disease and its use is well studied in the knee. Some of
this data can be extrapolated to its application for the hip;
however, this is not adequate to make an evidence-based
decision for clinical practice.
To date only eight trials examining the efficacy of intra-
articular corticosteroid hip injection for osteoarthritis have been
published [15–22]. Of these, only four are randomized con-
trolled trials (RCTs) [15–18]. There remains many questions
about the use of steroid injection for hip arthritis. These include:
injection technique, including fluoroscopic-guidance, ultra-
sound-guidance, or the use of anatomic landmarks; measuring
efficacy; and safety. Some of these safety issues are: difficult
access to the joint, introduction of infection, rapid progression
of arthritis following injection, and the potential adverse effect
on the eventual outcome of a total hip replacement.
This review article examines the above-published trials
of intraarticular corticosteroid injection of the hip as well as
other literature as it relates to the management of osteoar-
thritis of the hip in an attempt to discuss the potential benefit
and safety of this intervention.
Methods
Search strategy
A search of the following databases and journals was done:
Medline Systematic Reviews, the Cochrane Library,
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American Family Physician, Clinical Journal of Sports
Medicine, British Journal of Sports Medicine, Pubmed,
Clinics in Sports Medicine, ACP Journal Club, Agency for
Healthcare Research Quality, Institute for Clinical Systems
Improvement, Ortho Clinics, Journal of American Academy
of Orthopedic Surgeons, Journal of Orthopedic Research,
American Journal of Orthopedics, OVID. The following
search keywords were used with ‘‘and’’ inclusion criteria:
‘‘Hip Injection’’ (narrowed using ‘‘Intraarticular Hip Injec-
tion’’ and ‘‘Hip Corticosteroid Injection’’), ‘‘Intraarticular
Hip,’’ ‘‘Intraarticular Injection Number,’’ and ‘‘Hip Osteo-
arthritis’’ (narrowed using ‘‘Hip Osteoarthritis Injection’’).
Selection criteria
Inclusion: randomized controlled studies, blinded studies,
longitudinal clinical outcome studies, retrospective analy-
sis studies, review articles, and case reports. Articles
relevant to hip injections and in particular the safety of
such injections, indications for, procedure/technique used,
treatment of osteoarthritis, and adverse outcomes of such
injections. Exclusion: articles published before 1955, edi-
torial letters, poster sessions, and book extracts.
Search results
After literature search, only eight published trials looking
at the efficacy of intraarticular corticosteroid hip injection
for osteoarthritis were found. Of these, four studies are
RCTs. Three studies were found looking at infection risk
after total hip replacement following pre-operative intra-
articular corticosteroid injection. Seventeen published
review articles and guideline statements were found dis-
cussing the use of intraarticular corticosteroids for hip
osteoarthritis and three review articles and guideline
statements discussing the use of musculoskeletal ultra-
sound for hip injection were discovered. In addition to the
above, four case reports have been published discussing
adverse outcomes after hip intraarticular corticosteroid
injection, including septic arthritis and osteonecrosis.
Discussion
Therapeutic standards
There are a variety of published recommendations for the
management of hip osteoarthritis. More recently, a review
article from the Annals of the Rheumatic Diseases was
published in 2005 with evidence-based recommendations
for the management of hip osteoarthritis [7]. This journal is
the official publication of the European League Against
Rheumatism (EULAR), which provides task force reports
on the EULAR Standing Committee for International
Clinical Studies Including Therapeutics (ESCISIT). The
review study produced 10 proposed interventions for the
treatment of hip osteoarthritis. Five of the interventions are
supported by controlled-trial evidence and include: edu-
cation, non-steroidal anti-inflammatory drugs (NSAIDs),
cyclooxygenase-2 (COX-2) selective inhibitors (listed with
evidence separate from NSAIDs), opioids, and chondroitin.
Intraarticular steroid injection was included in the 10 pro-
posed interventions, but the review concluded that the
results from available studies are inconclusive and con-
trolled-trials are required.
Review articles published in 1995 and 2000 by the
American College of Rheumatology, provide guidelines on
the medical management of osteoarthritis of the hip [8, 9].
These guidelines are consistent with 2005 published
EULAR interventions including: patient education, physi-
cal exercise, and NSAIDs including COX-2 inhibitors.
Similar to the EULAR study, these guidelines provide no
conclusive recommendations for intraarticular injection of
corticosteroid. The authors state that steroid injection has
not been studied and if performed should be done under
radiologic guidance. Other published reviews and expert
opinion guidelines on the management of hip osteoarthritis
also provide little evidence for the use of intraarticular
steroid injection [10, 11, 13, 14, 23–25].
Indications & contraindications
Indications for intraarticular injection should be considered
in this article. A review paper published in The American
Journal of Orthopedics in 2000 provided an updated over-
view on the use of intraarticular corticosteroids [11]. Among
the clinical uses discussed, osteoarthritis of the knees,
ankles, shoulders, acromioclavicular joints, and first meta-
carpophalangeal and metatarsophalangeal joints, as well as
lumbar facet arthropathy are listed as common indications
for injection. Notably, hip osteoarthritis was not listed.
Clinics in Sports Medicine published a review on the use of
injections for joint osteoarthritis in sports [26]. The authors
state that, based on available literature, injection of small
non-weight-bearing joints may have better results as com-
pared to larger weight-bearing joints. More specific to the
hip, a study looking at the safety and efficacy of intraartic-
ular hip injection stated the following as additional
indications: use diagnostically to determine the likelihood of
achieving pain relief after hip arthroplasty; and as treatment
of arthritic symptoms in patients who are not candidates for
total hip arthroplasty [27]. In an expert opinion study of
orthopedic surgeons looking specifically at indications for
hip steroid injection, the majority of physicians studied lis-
ted diagnostic (hip vs. spine) and therapeutic pain relief [25].
Other possible indications or clinical situations when
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injection may be useful could include: when surgery is
contraindicated secondary to coexisting medical condition
and in young patients with whom there is concern for
longevity of hip prosthesis (Graphic 1).
A comprehensive list of contraindications for intra-
articular hip steroid injection is more widely accepted.
Absolute contraindications include: suspected or known
joint infection, presence of joint fracture, coagulopathy,
overlying cellulitis or infection, hypersensitivity to corti-
costeroids, and presence of prosthetic joint. Relative
contraindications include: anticoagulation therapy, joint
instability, poorly controlled diabetes, and adjacent skin
abrasions [11, 12, 25, 26].
Efficacy
As stated above, only eight published trials have been done
looking at the efficacy of intraarticular corticosteroid hip
injection for osteoarthritis and of these only four are RCTs
(Graphic 2). The most promising and recent study was
published in 2007 in Arthritis & Rheumatism [15]. Lambert
et al. carried out a double-blinded, placebo-controlled trial
of 52 patients with hip osteoarthritis. The patients were
randomized to intraarticular hip injection of corticosteroid
treatment (10 mg bupivicaine and 2 ml of triamcinolone) or
placebo (10 mg bupivicaine and 2 ml of saline) via
fluoroscopic guidance. The results revealed significant
improvement in pain and function in the treatment group at
three months of follow-up. No significant adverse events
were observed and there was no difference in the frequency
of adverse events noted between study groups. The results
from this trial offer very convincing evidence that intraar-
ticular corticosteroid injection can be an effective therapy
for osteoarthritis-related hip pain. Lambert et al. propose
that future research should explore the benefits of repeated
injection and the effect of injection on disease modification.
In a prior randomized controlled trial, Qvistgaard et al.
randomized 101 patients to: three intraarticular injections
of saline, one intraarticular injection of corticosteroid fol-
lowed by two sham injections, or three intraarticular
injections of hyaluronic acid [16]. The injections were done
via ultrasound guidance at 14-day intervals and a primary
outcome of ‘‘pain on walking’’ was used via the visual
analogue scale (VAS). Evaluation was done at baseline and
after 14, 28, and 90 days. The authors showed a significant
improvement and clinical effect in the corticosteroid group
as compared with the placebo; however, the effect was
very short-lived with no effect observed at the 3-month
follow-up. Of note, there was no statistically significant
change in any primary outcome with the hyaluronic acid
series. They concluded that there was a definite short-lived
effect that would indicate a use for intraarticular steroid
injection in the treatment of hip OA for acute pain relief.
The study also showed an association between presence of
hip joint effusion and good clinical response.
Kullenberg et al. published a prospective, double-blin-
ded study of 80 patients randomized to intraarticular
injection of either corticosteroid (without anesthetic) or
local anesthetic [17]. Patients were followed for pain,
functional ability, range of motion, and analgesics con-
sumed at 3- and 12-week intervals. The authors found that
pain for all modalities, the most being pain at rest,
decreased after corticosteroid injection at both the 3- and
12-week follow-up, with no improvement found in patients
treated with local anesthetic. The study suggests that
intraarticular injection might improve pain and range of
motion in hip osteoarthritis.
A prospective controlled study of 35 patients, done by
Flanagan et al. in 1988, found an insignificant difference
between saline, bupivicaine only, or bupivicaine with tri-
amcinolone injection in patients awaiting hip replacement
[18]. Patients in this study, however, were told that they
would be given priority for surgery if their pain worsened
after injection and therefore were biased toward a negative
result.
Trials looking at steroid hip injection for osteoarthritis
date back to 1956, when Leveaux and Quin published a
study investigating the effect of hydrocortisone and lido-
caine compared to lidocaine alone [22]. Their initial study
showed a greater symptomatic improvement in the patients
treated with hydrocortisone. Other subsequent studies
have shown similar short-term results, but these are not
randomized controlled trials and have subsequent bias in
the results. Smith et al. showed a 69% improvement in hip
pain 3 months after intraarticular injection of hydrocorti-
sone and lidocaine [20]. In another study, Plant et al.
demonstrated improvement in pain and internal rotation up
to 12 weeks following injection of methylprednisolone and
lidocaine in 45 patients, 27 of whom had osteoarthritis as
the indication for injection [19]. Of note, however, is the
patients in the study experienced a return of their pain by
the 26-week follow-up. The authors also were following
the radiographic pattern of response to injection in these
patients, and suggest that the radiographic severity of the
Graphic 1 Indications for hip intraarticular corticosteroid injection
1. Diagnostic test to determine if hip pain is secondary to hip versus
spine pathology.
2. Diagnostic test to determine if hip pain is secondary to
intraarticular versus extraarticular pathology.
3. To help determine the likelihood of achieving pain relief with hip
arthroplasty.
4. When surgical intervention is contraindicated.
5. In a young patient with whom there is a concern for the longevity
of hip prosthesis.
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arthritis does not have an influence on response to injection
but that patients with atrophic changes on X-ray had no
significant benefit when compared to hypertrophic or
mixed bone response.
The most recent uncontrolled trial, submitted for pub-
lication in September of 2005, looked at the change in pain,
stiffness, and disability after intraarticular injection of two
different doses of methylprednisolone, 40 and 80 mg, in
120 patients with hip osteoarthritis [21]. In the 40 mg dose
group, the authors demonstrated a significant improvement
in pain and stiffness but not disability at the 6-week follow-
up with only an improvement in stiffness at 12 weeks. In
the 80 mg dose group, however, the authors showed a
beneficial effect in pain, stiffness, and disability at 6 weeks
and 12 weeks. They conclude that both groups showed a
beneficial effect and noted evidence of a dose response.
Technique
Intraarticular injection of the hip can be a challenging
procedure. The hip joint cannot be palpated and is adjacent
to important neurovascular structures. For this reason, there
are many publications in the literature regarding the appro-
priate technique for locating the joint to facilitate injection
[23, 27–35]. This also contributes to why intraarticular hip
injections are not used or studied as much as other joints, i.e.
the knee. In general, three techniques are utilized: anatomic
landmarks, fluoroscopic guidance, and ultrasound guidance.
Because of the significant potential for injury to the femoral
nerve, femoral artery, and lateral femoral cutaneous nerve
and the potential high rate of extraarticular injection, the use
of anatomic landmarks is not considered a desirable tech-
nique given the increasingly easy access to radiologic
guidance. Leopold et al. studied the safety and efficacy of
using anatomic landmarks for intraarticular hip injection
[27]. The authors injected 30 cadaver hips with methylene
blue dye. With a lateral approach, intraarticular injection
was successful 80% of the time, and an anterior approach
was successful only 60% of the time. Also, the authors noted
that with an anterior approach their needle contacted or
pierced the femoral nerve 27% of the time and was within
5 mm of the nerve 60% of the time. The lateral approach was
noted to be significantly safer showing that the needle never
came within 25 mm of any neurovascular structure. The
authors suggest based on the results of the study that a
lateral approach in concert with fluoroscopy or ultrasound
guidance may achieve the safest and most effective needle
placement.
Graphic 2 List of randomized control trials: intraarticular corticosteroid hip injection for osteoarthritis
Citation Authors Number of patients Study length Technique Outcomes Adverse outcomes
[15] Lambert et al. 52 6 months Fluoroscopic-guidance ; Pain—3 months No serious
adverse events; Stiffness—3 months
: Function—3 months (1 Pt—DVT)
[17] Kullenberg et al. 80 12 weeks Fluoroscopic-guidance ; Pain—12 weeks None reported
: ROM—12 weeks
[16] Qvistgaard et al. 101 90 days Ultrasound-guidance ; Pain—14 & 28 days No serious
adverse eventsNo relief—90 days
(3 Pts—Steroid flare)
[18] Flanagan et al. 35 12 months Fluoroscopic-guidance No effect Increased symptoms
with steroid
Graphic 3 Key points
1. There is a lack of randomized controlled trial data.
2. Available studies support a possible short-term benefit for patients
refractory to non-pharmacologic or NSAID therapy.
3. The use of radiological guidance is recommended.
4. Literature supports the use of musculoskeletal ultrasound to guide
injection.
5. With proper sterile technique, injection can be performed with a
low risk of serious adverse outcomes.
6. If total hip arthroplasty is planned, avoid injection within 2 months
of the surgery.
Graphic 4 Future research
Randomized controlled trials




What is the duration of benefit?
2. Safety and accuracy of musculoskeletal ultrasound-guidance for
hip intraarticular injection.
3. Incidence of joint sepsis after THA following pre-operative
intraarticular corticosteroid injection.
4. What is the benefit of repeated injections?
5. What is the effect of injection on disease modification?
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Further literature search supports the conclusions of the
Leopold et al. study, and in general, more recent published
articles have supported the use of ultrasound over fluoro-
scopic guidance for injection. A report from the Archives of
Physical Medicine & Rehabilitation, published in 2006,
describes an office-based technique for ultrasound-guided
intraarticular hip injection [28]. The authors of the study,
Drs. Smith and Hurdle, list many advantages of ultrasound
as compared to fluoroscopy. These include: accessibility,
compact size, lack of radiation exposure, and visualization
of neurovascular and other soft-tissue structures. Other
results and recommendations from the rheumatologic and
radiology literature are also consistent with the Smith and
Hurdle report [29, 34, 35].
Safety
As for any intraarticular joint injection, various side effects
may occur with intraarticular hip injection. These may
include: pain with injection, post-injection flare, skin pig-
ment changes, fat atrophy, and joint infection. Systemic
effects can also occur and include: disruption of diabetes
and hypertension control, facial flushing, inhibition of
the hypothalamo–pituitary–adrenal axis, sepsis, and death
[10–12, 36].
Specifically for the hip, literature review reveals three
side effects of particular concern. These include: septic
arthritis, osteonecrosis, and the risk of joint infection after
total hip replacement following pre-operative intraarticular
corticosteroid injection. Significant research has been done
looking at joint sepsis following knee injection with inci-
dences ranging from 1 in 3,000 to 1 in 5,000 [37]. The
incidence of septic arthritis in the hip has not been as thor-
oughly studied. During literature search for this review
article, 2 case reports of septic hip arthritis following
corticosteroid injection were found. Nallamshetty et al.
documented a case of hip septic arthritis in a 65-year-old
woman after intraarticular injection of betamethasone and
lidocaine mixture via fluoroscopic guidance for hip pain
secondary to osteoarthritis [38]. The patient returned
3 weeks later with increasing pain and was shown to have
extensive joint destruction on plain films and MRI. Hip
aspirate at that time was positive for alpha-hemolytic
Streptococcus. The patient required subsequent resection
arthroplasty of the hip 2 months after presentation second-
ary to the joint destruction. The only other case report found
in the literature was submitted by Chazerain et al. in 1999
[39]. Their case showed septic hip arthritis in a 51-year-old
man following 10 intraarticular injections of sodium hyal-
uronate and one injection of triamcinolone between April
1995 and October 1998. The steroid injection was performed
in April 1998. The patient presented with septic arthritis in
October 1998 after the last sodium hyaluronate injection.
The infection was likely secondary to the increased exposure
from performance of multiple repeat injections and not
likely specific to the corticosteroid therapy.
Osteonecrosis of the femoral head after intraarticular
corticosteroid injection has also been reported in the litera-
ture. Four case reports were found, but three of these four
were following corticosteroid injection of other joints,
including shoulder, knee, and ankle [40, 41]. The fourth case
report discussed a 50-year-old female patient who received a
single injection of methylprednisolone and sensorcaine into
the hip joint, in which rapid collapse of the femoral head was
noted within a 3-month period of time [42]. Osteonecrosis
was found on subsequent histologic analysis. General con-
sensus proposes that osteonecrosis after joint injection is
more likely related to the severity of the underlying disease
and represents a natural progression of that disease rather
than a side effect of the injection itself.
The safety of intraarticular corticosteroid injection of
the hip prior to ipsilateral total hip replacement has also
been called into question because of concerns for an
increased incidence of post-operative joint infection. A
paper submitted by Kaspar and de V de Beer, in 2005,
found in a retrospective cohort study of 80 patients a
significant increase in arthroplasty revision secondary to
infection in patients who had intraarticular steroid injection
prior to hip replacement [43]. The mean time between
injection and surgery was 11 months, with an incidence of
10% in those who received injection compared to 0% in
those who did not. The authors proposed that intraarticular
injection of corticosteroid should be considered as rela-
tively contraindicated in patients who are candidates for
hip replacement. Two subsequent retrospective studies
exploring the relationship between injection and post-
operative infection do not show results consistent with the
findings of the Kaspar and de V de Beer study. McIntosh
et al. found in a cohort study of 437 patients, with a mean
time of 112 days between injection and surgery, no
significant relationship between injection and post-opera-
tive rates of infection [44]. However, in the patients who
had injection and subsequent infection, the mean time
between interventions was 44 days. This was not statisti-
cally significant. The authors caution giving injections less
than 2 months prior to hip replacement surgery. A recent
study published in The Journal of Bone and Joint Surgery
found in 36 patients, with a mean time between injection
and surgery of 18 months, no cases of deep joint sepsis
during a mean follow-up time of 25.8 months [45].
Conclusions
In general, there is still a lack of RCTs studying the
effectiveness and safety of intraarticular steroid injection
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for the treatment of hip osteoarthritis. However, current
data from available RCTs and other uncontrolled studies
demonstrate strong evidence that steroid injection can
provide a short-term reduction in pain. Published guide-
lines state a probable benefit for patients refractory to
non-pharmacologic or analgesic and NSAID therapy. If
intraarticular hip injection is performed, the current liter-
ature supports the use of radiological guidance and there is
evidence supporting the use of musculoskeletal ultrasound.
There are case reports in the literature describing septic
arthritis following hip injection but these are rare and may
be avoided with proper sterile technique. Also, the current
literature does not support an increased incidence of
infection after total hip replacement following pre-opera-
tive intraarticular corticosteroid injection. However, there
are no RCTs studying this adverse outcome and the current
data is conflicting (Graphic 3). Additional RCTs are needed
to adequately assess the efficacy and safety of corticoste-
roid injection therapy in hip osteoarthritis (Graphic 4).
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